FDA Authorizes Promising New Brain Cancer Drug Phase II Trial
Phase I dose escalation of NEO212 established tolerability up to 810 mg orally once daily on Days 1–5 of...
Encaleret Normalizes Calcium in Phase 2 Hypoparathyroidism
In a 10-patient Phase 2 proof-of-concept study in post-surgical hypoparathyroidism, 80% of participants on encaleret achieved concomitant normalization of...
Junshi’s Psoriasis Drug JS005 Succeeds in Phase 3 Trial
Junshi Biosciences reported that its anti–IL-17A monoclonal antibody JS005 met both co-primary endpoints—PASI 90 and sPGA 0/1 at Week...
Rapport to Announce RAP-219 Phase 2a Seizure Trial Results
Rapport Therapeutics will release topline results from its Phase 2a study of RAP-219 in drug-resistant focal onset seizures on...
Gelteq’s Pioneering Allergy Gel Starts Preclinical Trial
Gelteq plans to begin a preclinical bioequivalence program in September 2025 for a gel-based oral formulation of a widely...
CG Oncology BOND-003 Shows Remarkable Durability at 24 Months
Cretostimogene reported a 24-month complete response rate of 41.8% (46/110) in BCG‑unresponsive high‑risk NMIBC, with 75.5% achieving a CR...
Hutchmed Highlights Successful New Lung Cancer Data for 2025
HUTCHMED will take a data-light but strategy-heavy slate to WCLC and CSCO next week, led by updated analyses from...
HUTCHMED Highlights New Lung Cancer Data at 2025 Conferences
HUTCHMED will use next week’s oncology meetings to surface a broad slate of lung and solid tumor readouts, led...
Successful Myriad MRD Clinical Data in The Lancet Oncology
Median systemic therapy–free survival split along ctDNA status in a Phase 2 oligometastatic clear-cell RCC study: patients with ctDNA-positive...
Breakthrough AVIM Data: Sustained Blood Pressure Reduction
Topline data: In long-term follow-up of MODERATO II participants (n=16; mean 3.6 years), atrioventricular interval modulation (AVIM) maintained a...